Patients suffering from advanced basal cell carcinoma (BCC) have very limited treatment options. Sonidegib selectively inhibits the growth of Hedgehog pathway-dependent tumors and can treat ...
The European Commission has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules, from Novartis, for the treatment of adult patients...
Novartis announced the FDA has approved Odomzo (sonidegib, formerly LDE225) 200 mg capsules for the treatment of adult patients with...
The Hedgehog (Hh) pathway is critical for cell differentiation, tissue polarity, and stem cell maintenance during embryonic development, but is silent in adult tissues under normal conditions.
Sun Pharmaceutical Industries Ltd and its subsidiaries or associate companies announced its plans to acquire a branded oncology product, Odomzo...
BeiGene, Ltd. announced that the FDA has approved Tevimbra (tislelizumab-jsgr) as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor . Tevimbra will be available in the U.S. in the second half of 2024.
Avelumab is a promising new therapeutic agent for patients with metastatic Merkel cell carcinoma, a rare and aggressive type of neuroendocrine tumor of the skin.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent type of malignancy in Caucasians worldwide. Several factors have been correlated with aggressiveness and likelihood of recurrence...
On 25 June 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...